BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20966329)

  • 21. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET.
    Hara T; Inagaki K; Kosaka N; Morita T
    J Nucl Med; 2000 Sep; 41(9):1507-13. PubMed ID: 10994730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.
    Markovina S; Duan F; Snyder BS; Siegel BA; Machtay M; Bradley JD
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):597-605. PubMed ID: 26461002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
    Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
    Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18F alpha-methyl tyrosine PET studies in patients with brain tumors.
    Inoue T; Shibasaki T; Oriuchi N; Aoyagi K; Tomiyoshi K; Amano S; Mikuni M; Ida I; Aoki J; Endo K
    J Nucl Med; 1999 Mar; 40(3):399-405. PubMed ID: 10086702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standard uptake value predicts survival in non-small cell lung cancer.
    Okereke IC; Gangadharan SP; Kent MS; Nicotera SP; Shen C; DeCamp MM
    Ann Thorac Surg; 2009 Sep; 88(3):911-5; discussion 915-6. PubMed ID: 19699919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
    Inoue T; Koyama K; Oriuchi N; Alyafei S; Yuan Z; Suzuki H; Takeuchi K; Tomaru Y; Tomiyoshi K; Aoki J; Endo K
    Radiology; 2001 Jul; 220(1):54-62. PubMed ID: 11425972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
    Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
    J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
    Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
    Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of (18)F-2-deoxy-fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer.
    Ozawa Y; Hara M; Sakurai K; Nakagawa M; Tamaki T; Nishio M; Shibamoto Y
    Acta Radiol; 2010 Mar; 51(2):150-5. PubMed ID: 20092375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography.
    Shiraishi K; Nomori H; Ohba Y; Kaji M; Mori T; Shibata H; Oya N; Sasaki J
    Ann Thorac Cardiovasc Surg; 2010 Dec; 16(6):394-400. PubMed ID: 21263419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas.
    Lee SW; Nam SY; Im KC; Kim JS; Choi EK; Ahn SD; Park SH; Kim SY; Lee BJ; Kim JH
    Radiother Oncol; 2008 May; 87(2):211-6. PubMed ID: 18237806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
    Yilmaz M; Adli M; Celen Z; Zincirkeser S; Dirier A
    Nucl Med Commun; 2010 Jun; 31(6):526-31. PubMed ID: 20215979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
    Karam M; Roberts-Klein S; Shet N; Chang J; Feustel P
    J Nucl Med; 2008 Sep; 49(9):1429-36. PubMed ID: 18765585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.